Compare · BNR vs HUM
BNR vs HUM
Side-by-side comparison of Burning Rock Biotech Limited (BNR) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNR and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $42.74B, about 446.8x BNR ($95.7M).
- Over the past year, BNR is up 193.4% and HUM is up 52.7% - BNR leads by 140.7 points.
- HUM has hit the wire 4 times in the past 4 weeks while BNR has been quiet.
- HUM has more recent analyst coverage (25 ratings vs 2 for BNR).
- Company
- Burning Rock Biotech Limited
- Humana Inc.
- Price
- $9.10-1.78%
- $355.91+1.64%
- Market cap
- $95.7M
- $42.74B
- 1M return
- -46.80%
- +43.90%
- 1Y return
- +193.39%
- +52.72%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 4
- Recent ratings
- 2
- 25
Burning Rock Biotech Limited
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene. The company was founded in 2014 and is headquartered in Guangzhou, China.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest BNR
- Amendment: SEC Form SCHEDULE 13G/A filed by Burning Rock Biotech Limited
- Burning Rock Publishes 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by Burning Rock Biotech Limited
- SEC Form 4 filed by Han Yusheng
- Burning Rock Announces Founder's Purchase of Its ADSs
- SEC Form 3 filed by new insider Deng Feng
- SEC Form 3 filed by new insider Hayes Wendy W.
- New insider Han Yusheng claimed ownership of 17,357,806 units of Ordinary Shares (SEC Form 3)
- New insider Zhang Zhihong claimed ownership of 1,061,990 units of Ordinary Shares (SEC Form 3)
- SEC Form 3 filed by new insider Hu Xiaozhi
Latest HUM
- Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Humana completes $83 million Florida infrastructure investment to deepen coordinated patient care approach
- Humana upgraded by Deutsche Bank with a new price target
- Humana Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Humana, CenterWell and USAA Unite with VFW for National Day of Service Supporting Veterans Experiencing Homelessness
- Humana Invests More Than $1 Million to Advance Health Outcomes Across Louisiana
- Chief Financial Officer Mellet Celeste gave a grant of 15,387 units of Humana Common, decreasing direct ownership by 28% to 39,637 units (SEC Form 4)
- Chief Information Officer Mehta Japan was granted 9,448 units of Humana Common, increasing direct ownership by 122% to 17,176 units (SEC Form 4)
- President, Enterprise Growth Dintenfass David was granted 11,273 units of Humana Common, increasing direct ownership by 80% to 25,407 units (SEC Form 4)
- President & CEO Rechtin James A. was granted 35,633 units of Humana Common (SEC Form 4)